Scancell Holdings Plc

Type: Company
Name: Scancell Holdings Plc
First reported Apr 04 2014 - Updated Apr 04 2014 - 2 reports

SCANCELL : To Announce Phase I/II Of Melanoma Clinical Trial On April 8

LONDON ( Alliance News ) - Scancell Holdings PLC Friday said that it will announce the results of phase one and two of its clinical trial in patients with stage three and four melanoma at the American Association for Cancer Research annual meeting in ... [Published 4 Traders - Apr 04 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

This week: Flowgroup fully charged, Venture Life’s a peach on AIM

AVCT update on affirmers,BILL final results,BJU full year results,CPP disposal,EHP interim results,FLOW order from Trane,HZM PFS results,MSMN first day of dealings,SCHO intention to float on AIM,SCLP study on track,SMA placing,Tekcapital intention to ... [Published Proactiveinvestors United Kingdom website - Mar 27 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 1 reports

Scancell Hlds : 8mg Higher Dose SCIB1 Study On Track

Scancell Holdings Plc('Scancell' or the "Company")8mg Higher Dose SCIB1 Study On TrackScancell Holdings Plc, (AIM:SCLP)Following preliminary evidence from Part 1 of the study showing that a 4mg dose of SCIB1 produced an immune response that might be associated ... [Published Investegate - Mar 21 2014]
First reported Feb 11 2014 - Updated Feb 11 2014 - 2 reports

Scancell shares rise to 2month high on FDA orphan drug designation

Shares in Scancell Holdings (LON:SCLP) rose to a two-month high after US Food and Drug Administration granted orphan drug designation (ODD) to the company’s SCIB1 ImmunoBody for the treatment of later-stage cancer.“We believe that the aw...Related Biotechnology, ... [Published BioPortfolio - Feb 11 2014]
First reported Dec 16 2013 - Updated Dec 16 2013 - 1 reports

Scancell Holdings receives Japanese patent for DNA ImmunoBody technology

Scancell Holdings, a developer of novel immunotherapies for the treatment of cancer, has received a key patent for its DNA ImmunoBody technology in Japan. This key patent follows approval in Australia earlier this year and adds to Scancell’s growing body ... [Published PharmaBiz - Dec 16 2013]
First reported Dec 09 2013 - Updated Dec 09 2013 - 1 reports

New data for SCIB1 in metastatic melanoma

Scancell Holdings PlcCompelling new immune response data and promising survival trend suggest potential for SCIB1 as an effective novel therapy in metastatic melanomaScancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies ... [Published TrustNet - Dec 09 2013]
First reported Nov 21 2013 - Updated Nov 21 2013 - 1 reports

AIM Notice - 21/11/2013

? NOTICE 21/11/2013 - 8:00AM The London Stock Exchange admits the following securities to trading on AIM: CELTIC PLC 14,984 ORDINARY SHARES OF 1P EACH, FULLY PAID (0433918)(GB0004339189) EDGE RESOURCES INC 35,000,006 COMMON SHARES OF NO PAR VALUE FULLY ... [Published TrustNet - Nov 21 2013]
First reported Nov 19 2013 - Updated Nov 19 2013 - 1 reports

This week: Atlantic goes to China, US Bureau extends SPA, IVO on a mission, IPO boost for IPO, EC approval for PLE

Stock markets continue to trade sideways in a narrow range reflecting the anxiety ahead of the Federal Reserve’s release of October FOMC minutes. A series of speaker events prior to the Fed release is also adding to nervousness as investors look for ... [Published Proactiveinvestors United Kingdom RSS feed - Nov 19 2013]
First reported Nov 01 2013 - Updated Nov 01 2013 - 1 reports

AGM Statement

Scancell Holdings Plc ('Scancell') Results of AGM Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, announces that all resolutions proposed at the Annual General Meeting held today were duly passed. ... [Published TrustNet - Nov 01 2013]

Quotes

...BrainJuicer grew in all other geographies that they operate in other than Germany. John Kearon, Founder and Chief Juicer of BrainJuicer, said: "We have made a promising start to 2014. As always, however, given our limited revenue visibility we cannot predict with any certainty how the year will unfold. What we do know is that the coming years will be exciting”. "
Richard Goodfellow, Joint CEO of Scancell, said: "Our higher dose 8mg SCIB1 study is progressing well. In view of the continued safety profile of SCIB1 at the higher dose, we are now recruiting for Part 2 of this cohort, which will assess the immune and clinical response to SCIB1 in a larger number of patients with Stage III/IV melanoma. We look forward to reporting the results from Part 1 of the study later this year."
NEXT ARTICLE More From BioPortfolio on "Scancell shares rise to 2-month high on FDA orphan drug designation"
Scancell Holdings plc ( "Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce encouraging results from Part 2 of its on-going Phase 1/2 clinical trial in patients with Stage III/IV melanoma treated with the SCIB1 ImmunoBody Ò as well as an update from patients in Part 1 of the study."

More Content

All (17) | News (15) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
SCANCELL : To Announce Phase I/II Of Melanoma C... [Published 4 Traders - Apr 04 2014]
Scancell to present Phase I/II data for SCIB1 [Published Interactive Investor - Apr 04 2014]
This week: Flowgroup fully charged, Venture Lif... [Published Proactiveinvestors United Kingdom website - Mar 27 2014]
Scancell Hlds : 8mg Higher Dose SCIB1 Study On ... [Published Investegate - Mar 21 2014]
Scancell shares rise to 2month high on FDA orph... [Published BioPortfolio - Feb 11 2014]
Scancell shares rise to 2-month high on FDA orp... [Published Proactiveinvestors United Kingdom website - Feb 11 2014]
Scancell Holdings receives Japanese patent for ... [Published PharmaBiz - Dec 16 2013]
New data for SCIB1 in metastatic melanoma [Published TrustNet - Dec 09 2013]
AIM Notice - 21/11/2013 [Published TrustNet - Nov 21 2013]
This week: Atlantic goes to China, US Bureau ex... [Published Proactiveinvestors United Kingdom RSS feed - Nov 19 2013]
AGM Statement [Published TrustNet - Nov 01 2013]
Director/PDMR Shareholding [Published TrustNet - Oct 22 2013]
Investor Update [Published TrustNet - Oct 01 2013]
Investor Day [Published TrustNet - Sep 10 2013]
Scancell's DNA ImmunoBody technology receives A... [Published PharmaBiz - Sep 04 2013]
AIM Notice - 05/08/2013 [Published TrustNet - Aug 05 2013]
AIM Notice - 02/08/2013 [Published TrustNet - Aug 02 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
This week: Flowgroup fully charged, Venture Lif... [Published Proactiveinvestors United Kingdom website - Mar 27 2014]
AVCT update on affirmers,BILL final results,BJU full year results,CPP disposal,EHP interim results,FLOW order from Trane,HZM PFS results,MSMN first day of dealings,SCHO intention to float on AIM,SCLP study on track,SMA placing,Tekcapital intention to ...
Scancell shares rise to 2-month high on FDA orp... [Published Proactiveinvestors United Kingdom website - Feb 11 2014]
Shares in Scancell Holdings ( LON:SCLP ) rose to a two-month high after US Food and Drug Administration granted orphan drug designation (ODD) to the company’s SCIB1 ImmunoBody for the treatment of later-stage cancer. “We believe that the award of ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.